Retatrutide
Retatrutide works by activating three distinct receptors: GLP-1, which helps regulate appetite and blood sugar; GIP, which boosts insulin response and contributes to metabolic regulation; and glucagon, which promotes energy expenditure and fat breakdown. Together, these actions create a combined effect that enhances overall efficacy.
Also known as: LY3437943, Triple G
A triple-acting agent that activates GLP-1, GIP, and glucagon receptors. In phase 3 studies, it has demonstrated an average weight reduction of up to 28.7%—equivalent to about 71 pounds—marking the greatest weight loss observed with any anti-obesity medication to date.
•Current status: Phase 3 trials ongoing. The TRIUMPH-4 trial (expected completion December 2025) reported a mean weight loss of 28.7%, the highest recorded in an obesity clinical study. A New Drug Application is anticipated between Q4 2026 and Q1 2027. Evidence based on human clinical trials.
•Standard dosing: 4–12 mg administered once weekly on the same day each week via subcutaneous injection.
•Primary research focus: Weight management, metabolic syndrome, and reduction of liver fat.
•Current status: Phase 3 trials ongoing. The TRIUMPH-4 trial (expected completion December 2025) reported a mean weight loss of 28.7%, the highest recorded in an obesity clinical study. A New Drug Application is anticipated between Q4 2026 and Q1 2027. Evidence based on human clinical trials.
•Standard dosing: 4–12 mg administered once weekly on the same day each week via subcutaneous injection.
•Primary research focus: Weight management, metabolic syndrome, and reduction of liver fat.
Reviews
There are no reviews yet.